HIV-associated nephropathy

Summary

HIV-associated nephropathy (MONDO:0005798) is a disease and 4 clinical trials. Top therapeutic interventions include lamivudine, nelfinavir mesylate, and saquinavir. A subtype of inherited focal segmental glomerulosclerosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	HIV-associated nephropathy
Mondo ID	MONDO:0005798
EFO	EFO:0007313
MeSH	D016263
NCIT	C26918
UMLS	C0078911
MedGen	37145
GARD	0024232
Is cancer (heuristic)	no

Also known as: AIDS-associated nephropathy · AIDS-related nephropathy · HIV nephropathy · HIVAN

Disease family

This is a subtype of inherited focal segmental glomerulosclerosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inherited kidney disorder › inherited focal segmental glomerulosclerosis › HIV-associated nephropathy

Related subtypes (7): focal segmental glomerulosclerosis 1, focal segmental glomerulosclerosis 2, focal segmental glomerulosclerosis 5, focal segmental glomerulosclerosis 6, focal segmental glomerulosclerosis 7, focal segmental glomerulosclerosis 8, focal segmental glomerulosclerosis 9

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

4 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Lamivudine	Phase 3
Saquinavir	Phase 3
Stavudine	Phase 3
Prednisone	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00002397	PHASE3	COMPLETED	A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease
NCT00000819	PHASE2	COMPLETED	A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
NCT05685810	Not specified	ACTIVE_NOT_RECRUITING	Genetic Determinants of Kidney Disease in People of African Ancestry With HIV
NCT00153621	Not specified	COMPLETED	Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAMIVUDINE	4	1
NELFINAVIR MESYLATE	4	1
SAQUINAVIR	4	1
STAVUDINE	4	1
CHEMBL18314	0	1
CHEMBL365442	0	1
CHEMBL418334	0	1
CHEMBL4575419	0	1